The 2018 Improving Outcomes in the Treatment of Opioid Dependence (IOTOD) conference is sponsored by the following companies:
INDIVIOR is the world leader in addiction treatment, with over twenty years of experience and a unique patient focussed approach. People with addiction are often stereotyped and discounted, creating an environment where many are undiagnosed, under-treated and under-supported.
INDIVIOR has actively partnered with health-care professionals, the public health community, policymakers and payers to humanise people suffering from addiction, and to treat addiction as a chronic condition rather than a social disorder. Our belief is that people with addiction should be treated as patients, just like other chronic disease sufferers.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercialises innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, we seek to improve the care of patients living with life-threatening diseases around the world. Gilead’s therapeutic areas of focus include HIV/AIDS, liver diseases, haematology and oncology, inflammatory and respiratory diseases, and cardiovascular conditions.
The Mundipharma global network of privately-owned independent associated companies was founded in 1956 by doctors, and now operates in over 120 countries worldwide. We are focused on developing business partnerships to identify and accelerate meaningful technology across an increasingly diverse portfolio of therapy areas including respiratory, oncology, pain, and biosimilars. Consistent with our entrepreneurial heritage, we like to think we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems.
For more information please visit: www.mundipharma.com
Martindale Pharma is a leading UK-based specialty pharmaceutical company providing essential medicines to over 50 countries around the world. The company specializes in the field of opioid dependence, emergency care and sterile injectables. In 2013 Martindale Pharma launched Prenoxad Injection, the world’s first licensed Take Home Naloxone kit for use in the community setting, and in 2017 launched Espranor buprenorphine oral lyophilisate continuing the company’s commitment to the treatment of opioid dependence. Martindale Pharma recently became part of the Ethypharm Group of companies, strengthening their presence in the UK and broadening their global reach.